Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
TARS disclosed notices under Rule 144 for transactions in its common stock. The filing lists a Restricted Stock Vesting entry of 3,610 shares dated 03/17/2026 attributed to Fidelity Brokerage Services LLC as compensation. The filing also records sales by Seshadri Neervannan of 8,366 shares on 03/04/2026 and 3,125 shares on 03/17/2026, with proceeds shown alongside each sale.
TARS files a Form 144 notice to sell 2,133 shares of Common Stock following restricted stock vesting on 03/17/2026.
The filing shows the shares are tied to compensation (restricted stock vesting). The excerpt also reports that Jeffrey Farrow sold 2,111 shares on 03/17/2026. Trading venue is listed as NASDAQ.
Aziz A. Mottiwala reports an intention to sell Common stock. The filing lists 4,330 shares of Common stock to be sold in connection with restricted stock vesting tied to compensation, with the action dated 03/17/2026 and the security shown on NASDAQ.
The filing also reports 4,286 shares of Common stock sold during the prior three months, dated 03/17/2026. The entries identify a brokerage address for Fidelity Brokerage Services LLC.
TARS submitted a Form 144 notice reporting restricted stock vesting and related disposals of common shares. The filing lists 379 common shares tied to a Restricted Stock Vesting event on 03/17/2026. It also records that 375 common shares were sold during the past three months on 03/17/2026 by Elizabeth Yeu-Lin.
Tarsus Pharmaceuticals director William J. Link, PhD sold 12,500 shares of Common Stock in open-market transactions. The sales occurred on 2026-03-16 at weighted-average prices of $68.09, $69.03, and $69.75, under an automatic Rule 10b5-1 trading plan adopted on September 8, 2025. Following these trades, he continues to hold 116,332 shares directly.
Tarsus Pharmaceuticals, Inc. Chief Human Resources Officer Dianne C. Whitfield reported the settlement of vested Restricted Stock Units into common shares. On March 15, 2026, she exercised RSUs covering 23,909 underlying shares, resulting in direct ownership of 47,302 shares of common stock.
The RSUs were granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan on March 9, 2022, March 8, 2023, March 7, 2024, and March 5, 2025. Each grant vests in four equal annual installments on March 15 of consecutive years, subject to continuous service.
Tarsus Pharmaceuticals, Inc. reported that General Counsel Bryan Wahl acquired common shares through the settlement of vested restricted stock units (RSUs). On March 15, 2026, multiple RSU awards were exercised, delivering a total of 24,236 shares of common stock at an exercise price of $0.00 per share.
Following these transactions, Wahl held 76,399 shares of Tarsus common stock directly, which includes 451 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025. The RSUs were granted between 2022 and 2025 under the 2020 Stock Plan, with 25% of each grant vesting annually on March 15, subject to continued service.
Tarsus Pharmaceuticals, Inc. Chief Operating Officer Seshadri Neervannan reported equity compensation activity tied to restricted stock units. On March 15, 2026, vested RSUs were settled into 26,287 shares of common stock at an exercise price of $0.00 per share.
The RSUs were granted under the Tarsus 2020 Stock Plan across awards from 2022 through 2025, each vesting in four annual 25% installments on March 15, subject to continuous service. After these settlements, Neervannan directly holds 97,104 shares of common stock.
The filing also shows 475 shares of common stock held indirectly by his daughter, with an explicit disclaimer that he does not beneficially own those securities for Section 16 or other purposes.
Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala acquired 26,482 shares of common stock on March 15, 2026 through the settlement of vested Restricted Stock Units granted under the company’s 2020 Stock Plan. Each RSU converts into one share of common stock at no cash exercise price.
Following these transactions, Mottiwala directly holds 74,536 shares of Tarsus common stock. This total includes 497 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, reflecting ongoing equity-based compensation rather than open-market buying or selling.
Tarsus Pharmaceuticals, Inc. officer Jeffrey S. Farrow reported the settlement of vested Restricted Stock Units into common stock. On March 15, 2026, he acquired 13,042 shares of common stock upon exercise/settlement of RSUs granted under the company’s 2020 Stock Plan.
The filing indicates these RSUs were from grants made on March 7, 2024 and March 5, 2025, each vesting in four equal annual installments every March 15, subject to continued service. Following these transactions, Farrow directly holds 49,746 shares of Tarsus common stock.